Moran Shapira1, Hila Raanani2, Baruch Feldman2, Naama Srebnik3, Sanaz Dereck-Haim2, Daphna Manela2, Masha Brenghausen2, Liat Geva-Lerner4, Eitan Friedman2, Efrat Levi-Lahad5, Doron Goldberg3, Tamar Perri2, Talia Eldar-Geva3, Dror Meirow6. 1. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel. 2. Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel. 3. Division of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel. 4. Women and Children's Health Research Unit, Gertner Institute, Tel Hashomer, Israel. 5. Department of Medical Genetics, Shaare Zedek Medical Center, Jerusalem, Israel. 6. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; Division of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel. Electronic address: meirow@post.tau.ac.il.
Abstract
OBJECTIVE: To evaluate the association between carriage of BRCA1/2 mutations and ovarian performance, as demonstrated by in vitro fertilization (IVF) outcomes. DESIGN: Retrospective cohort study. SETTING: Two tertiary IVF centers. PATIENT(S): BRCA mutation carriers undergoing IVF for preimplantation genetic diagnosis (PGD) or fertility preservation were compared with non-BRCA PGD or fertility preservation patients, matched by age, IVF protocol, IVF center, and cancer disease status. INTERVENTION(S): In vitro fertilization cycles for PGD and fertility preservation. MAIN OUTCOME MEASURE(S): Outcome of IVF: oocyte yield, poor response rate, number of zygotes, pregnancy rates. RESULT(S): A total of 62 BRCA mutation carriers and 62 matched noncarriers were included; 42 were fertility preservation breast cancer patients, and 82 were PGD non-cancer patients. Mean (± SD) age of patients was 32 ± 3.58 years. Number of stimulation days and total stimulation dose were comparable between carriers and noncarriers. Their cycles resulted in comparable oocyte yield (13.75 vs. 14.75) and low response rates (8.06% vs. 6.45%). Number of zygotes, fertilization rates, and conception rates were also comparable. CONCLUSION(S): Both healthy and cancer-affected BRCA mutation carriers demonstrated normal ovarian response in IVF cycles.
OBJECTIVE: To evaluate the association between carriage of BRCA1/2 mutations and ovarian performance, as demonstrated by in vitro fertilization (IVF) outcomes. DESIGN: Retrospective cohort study. SETTING: Two tertiary IVF centers. PATIENT(S): BRCA mutation carriers undergoing IVF for preimplantation genetic diagnosis (PGD) or fertility preservation were compared with non-BRCA PGD or fertility preservation patients, matched by age, IVF protocol, IVF center, and cancer disease status. INTERVENTION(S): In vitro fertilization cycles for PGD and fertility preservation. MAIN OUTCOME MEASURE(S): Outcome of IVF: oocyte yield, poor response rate, number of zygotes, pregnancy rates. RESULT(S): A total of 62 BRCA mutation carriers and 62 matched noncarriers were included; 42 were fertility preservation breast cancerpatients, and 82 were PGD non-cancerpatients. Mean (± SD) age of patients was 32 ± 3.58 years. Number of stimulation days and total stimulation dose were comparable between carriers and noncarriers. Their cycles resulted in comparable oocyte yield (13.75 vs. 14.75) and low response rates (8.06% vs. 6.45%). Number of zygotes, fertilization rates, and conception rates were also comparable. CONCLUSION(S): Both healthy and cancer-affected BRCA mutation carriers demonstrated normal ovarian response in IVF cycles.
Authors: Jessica L Chan; Lauren N C Johnson; Mary D Sammel; Laura DiGiovanni; Chan Voong; Susan M Domchek; Clarisa R Gracia Journal: J Genet Couns Date: 2016-10-28 Impact factor: 2.537
Authors: Drechsel Katja C E; van Tilborg Theodora C; Eijkemans Marinus J C; Lentjes Eef G W M; Homminga Irene; Goddijn Mariette; van Golde Ron J T; Verpoest Willem; Lichtenbelt Klaske D; Broekmans Frank J M; Bos Anna M E Journal: Reprod Sci Date: 2022-06-15 Impact factor: 3.060
Authors: Christina N Cordeiro Mitchell; Bailey McGuinness; Eliana Fine; William G Kearns; Mindy S Christianson; James Segars; Lisa M Pastore Journal: J Assist Reprod Genet Date: 2020-03-24 Impact factor: 3.412
Authors: Felipe Cavagna; Anagloria Pontes; Mario Cavagna; Artur Dzik; Nilka F Donadio; Rafael Portela; Michelle T Nagai; Luiz H Gebrim Journal: Contemp Oncol (Pozn) Date: 2017-12-30